Glaxo's Stiefel unit to promote Amgen's Enbrel in U.S.

London

- The Stiefel unit of GlaxoSmithKline, based here, will promote Amgen’s Enbrel (etanercept) psoriasis treatment to U.S. dermatologists, Bloomberg News reports.

The partnership, according to a Glaxo statement, “has no impact” on another Amgen co-promotion agreement with Pfizer, which sells Enbrel outside the region and, with California-based Amgen, in North America. Enbrel is also approved to treat rheumatoid arthritis.

Glaxo agreed to buy Stiefel Laboratories, based in Coral Gables, Fla., for $2.9 billion in April 2009.